ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPercutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR) has gained interest as concomitant coronary artery disease (CAD) is now often treated conservatively before TAVR, and TAVR is increasingly used in younger patients with longer life expectancies. Therefore, more contemporary data on PCI after TAVR are warranted to optimize CAD treatment and guide lifetime management. The primary objective was to evaluate the incidence of PCI in patients with prior TAVR, including insights on trends and procedural and clinical outcomes from a large, nationwide cohort.
methodsData from the Netherlands Heart Registration were used to identify patients with prior TAVR who underwent PCI between January 2015 and September 2021.
resultsAmong 216,813 PCI patients, 419 (0.19%) had previously undergone TAVR, representing an incidence of 2.81% among all TAVR patients (n = 14,933) in the Netherlands. The annual proportion of PCI procedures after TAVR increased from 0.05% in 2015 to 0.39% in 2021 (p < 0.001). Procedural adverse events were low. Patients treated with self-expanding transcatheter heart valves (THVs) more frequently underwent PCI without stenting (17.8% vs. 10.1%, p = 0.049), though target vessel revascularization rates and all-cause mortality were comparable. Matched patients with and without prior TAVR had similar clinical outcomes.
conclusionsThe incidence of PCI after TAVR is low but increasing. Clinical outcomes are comparable between THV platforms, but self-expanding THVs were associated with higher rates of PCI without stent implantation. The growing need for PCI after TAVR underscores the importance of coronary access in lifetime management strategies by multidisciplinary heart teams.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.